We are live on ! Find out more
PSTV

Plus Therapeutics
PSTV

Delisted

PSTV was delisted on the 31st of July, 2026.

Back to rankings

Fund managers haven’t disclosed any holdings of PSTV yet.

PSTV Hedge Fund Activity: Q1 2026 in Review

23 of the 8,137 institutional investors tracked by Wall St. Rank reported a position in Plus Therapeutics (PSTV) for Q1 2026, worth a combined $1.49M — down 75% from $5.92M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of PSTV and 7 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 5 added.

The largest buyer was Geode Capital Management, adding an estimated $186K. The largest seller was L1 Global Manager, exiting entirely with an estimated $1.17M sold.

  • 23 institutional investors held Plus Therapeutics (PSTV) as of Q1 2026, down from 25 in Q4 2025.
  • Funds reported $1.49M of Plus Therapeutics stock for Q1 2026, down 75% quarter-over-quarter.
  • 7 funds opened new Plus Therapeutics positions in Q1 2026 and 8 closed out, a net change of -1 holder.
  • The largest Plus Therapeutics buyer in Q1 2026 was Geode Capital Management, an estimated $186K added.
  • The largest Plus Therapeutics seller in Q1 2026 was L1 Global Manager, an estimated $1.17M sold.

Based on aggregated 13F filings for Q1 2026.